Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities

Abstract

SummaryIrinotecan is a water-soluble camptothecin derivative with clinical activity against colorectal and small cell lung cancers and is currently a standard of care therapeutic in the treatment of colorectal cancer in combination with 5-fluorouracil. One of the major clinical issues limiting the use of irinotecan is gastrointestinal toxicity manifested as life-threatening diarrhea which is reported in up to 45 % of treated patients. The studies summarized here tested, in a rat model of irinotecan-associated gastro-intestinal toxicity, whether a lipid nanoparticle formulation of irinotecan, Irinophore C™, mitigated early-onset or late-onset diarrhea when given at doses equivalent to unformulated irinotecan that engenders both early- and late-onset diarrhea. Specifically, rats administered intravenously on two consecutive days with unformulated irinotecan at 170 mg/kg then 160 mg/kg experienced transient early-onset diarrhea after each administration and then experienced significant late-onset diarrhea peaking 4 days after treatment. Irinophore C™ given at the identical dose and schedule did not elicit either early- or late-onset diarrhea in any animals. When Irinophore C™ was combined with 5-fluorouracil there was also no early- or late-onset diarrhea observed. Histopathological analysis of the gastro-intestinal tract confirmed that the effects associated with irinotecan treatment were absent in rats given Irinophore C™ at the identical dose. Pharmacokinetic analysis demonstrated significantly higher systemic concentrations of irinotecan in rats given the nanoparticle formulation compared to those given unformulated irinotecan. These results demonstrate that the Irinophore C™ formulation is significantly less toxic than irinotecan, used either as a single agent or in combination with 5-fluorouracil, in a rat model of irinotecan-induced gastrointestinal toxicity.

Irinotecan and Δ9-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers

“…There have also been attempts to design a new delivery systems for IRI (liposomes, micelle solutions, microemulsions, etc.) [ 58 ], as well as to design nanoparticle drug formulations [ 59 ], which could ensure high systemic concentrations of the drug without producing severe gastrointestinal toxicity.…”

Phytochemicals in Chemoprevention: A Cost-Effective Complementary Approach

“…Tea catechins have also shown to have a protective effect against the effect of chemotherapy drugs on non-transformed cells in addition to their anticancer properties. Irinotecan (IT) is a chemotherapeutic drug with dose-limiting toxicity because of its severe effects on the small intestine [159]. Irinotecan treatment caused high levels of inflammation and lipid peroxidation due to myeloperoxidase (MPO) activity, as well as a drop in GSH concentration of the ileum of mice and an increase in the oxidized version of GSH, glutathione disulfide (GSSG) [160,161].…”

Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use

“…Based on previous studies, it was concluded that quercetin combined with irinotecan (CPT-11) could produce synergistic cytotoxic effects [26][27][28]. Our group has developed a liposomal CPT-11 formulation (Irinophore C) with significant therapeutic activity [29,30] and this gives us a favorable position to develop a combination product comprising CPT-11 and Fig. 6 Representative cryotransmission electron microscopy images of liposomes.…”